Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain

Completed · Phase 4

Conditions studied: Neuropathic Pain

In brief

The purpose of this study is to find out if Exalgo (r) is beneficial for the patients with neuropathic pain.

Key facts

Study ID

NCT01207596

Run by

International Clinical Research Institute

People needed

30

Starts

2010-09-01

Expected to finish

2011-09-01

Last updated by the study team

2012-06-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• individuals with chronic pain of more than 6 months duration
• pain is determined to be secondary to a documented neuropathy
• patients who are tolerant of opiates (60 mg of morphine or equivalent for at least one week)
• male or female patients aged 18-75 yrs and have signed a written informed consent form and privacy statement
• female patients of child-bearing potential must be using an acceptable form of birth control

You may not qualify if…

• pregnant or lactating women
• allergy to morphine or its derivatives
• history of alcohol or substance abuse in the last 3 yrs
• participation in any other clinical trial in the last 30 days
• uncontrolled pain
• patient who is deemed to be medically unstable by principal investigator
• history of severe lung disease or asthma that is deemed medically significant by principal investigator

Where it is running

• International Clinical Research Institute — Leawood, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.